Merck to pay $1.5M over environmental issues; APIs to star in next round of Big Pharma deal-making in India;

> Merck ($MRK) will pay a $1.5 million civil penalty to settle alleged violations of federal environmental laws--failing to take certain preventive measures, and noncompliance with reporting regulations--at two Pennsylvania facilities. Story

> Watch for active pharmaceutical ingredients to be at the center of coming M&A deals among Big Pharma and Indian drugmakers.  More

> The search for new cancer treatments is being sidetracked because pharma companies are unable to keep up with demand for clinical trial supplies. Story

> Pfizer ($PFE) and the National Association of Boards of Pharmacy have paired up to warn consumers about the risks of counterfeit prescription drugs. Item

> Roche last week cut the ribbon on a 17,000-square-foot clinical supply manufacturing facility at its Nutley, NJ campus, capable of producing dosage forms of highly potent compounds. Release

> H&P Industries has updated its March recall of Povidone Prep Pads to include Lee Medical International's Custom Dialysis Trays/Kits. Release

> Emergent BioSolutions ($EBS) has been awarded a 5-year contract to supply the U.S. government with 44.8 million doses of the BioThrax anthrax vaccine; total value could reach $1.25 billion. Release

> CryoPort ($CYRX) and MediRent will open a European Operations Center in Leiden, The Netherlands. Announcement

Suggested Articles

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.

Boehringer Ingelheim is investing $50 million in an animal health plant in Puerto Rico, adding 105 jobs.

Teva will begin producing chemo drug vincristine in the U.S. but has resisted the idea that its withdrawal from the market led to a shortage.